Drug Database
AN

anti-varicella zoster immunoglobulins

✓ Approved

Kedrion · Polyclonal Antibodies · Polyclonal Antibodies

What is anti-varicella zoster immunoglobulins?

anti-varicella zoster immunoglobulins is a polyclonal antibodies developed by Kedrion. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyKedrion
Drug ClassPolyclonal Antibodies, Antibody
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Kedrion

Therapeutic Indications

anti-varicella zoster immunoglobulins is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsVaricella zoster virus infection✓ Approved

Related Research Articles

PubMedJournal of clinical laboratory analysis2026-10-22

The Impact of Immunoglobulins on Cardiovascular Diseases and Lipid Profiles in Elderly and Middle-Aged Chinese Individuals: A 15-Year Retrospective Study.

Li Ya Y, Jiao Li L, Gao Yuan Y, Ni Xue-Feng XF

Humoral immunity defends via immunoglobulins. This study aimed to evaluate the association between immunoglobulins and CVDs and lipid profiles in a cohort of individuals aged 45 years and older. Data from 982 subjects were analyzed. The cohort had a median age of 61 years (IQR 56-72), was predominantly male (84.8%), and had a high prevalence of CVDs at baseline, including hypertension (30.3%), dyslipidemia (20.7%), arrhythmia (22.3%), coronary heart disease (12.1%), and atrial fibrillation (4.5%). Logistic regression analysis was used to examine the association between baseline and time-varying serum levels of IgG, IgA, and IgM and the presence of five CVDs: coronary heart disease, atrial fibrillation, arrhythmia, hypertension, and dyslipidemia. We additionally explored the relationship between these immunoglobulin levels and lipid profiles. No significant differences in immunoglobulin levels were found between CVD and non-CVD groups at baseline, and baseline immunoglobulin levels were not associated with any CVD. However, longitudinal changes in IgG and IgA levels were positively associated with changes in free fatty acids (FFAs). Intriguingly, longitudinal increases in IgM levels were positively associated with total cholesterol, LDL-C, non-HDL-C, and HDL-C. This study provides longitudinal evidence that increases in IgG and IgA levels are associated with elevated FFA levels, while increases in IgM are associated with an adverse lipid profile characterized by higher total cholesterol, LDL-C, and non-HDL-C, and lower HDL-C. These findings suggest a link between humoral immunity and lipid metabolism that warrants further investigation, with potential implications for cardiovascular risk assessment.

PMID 42902915
Read full article →
PubMedChemical Society reviews2026-10-22

Recent applications of asymmetric hydrogenation in total synthesis of natural products and drugs.

Li Dong D, Lu Jingya J, Zhang Yao Y, Duan Ya-Nan YN et al.

Natural products with unique structures and promising bioactivities are vital for drug discovery. The efficient and concise synthesis of these natural products and analogues thus becomes even more critical for further drug screening. Over the past several decades, asymmetric hydrogenation has witnessed remarkable progress and evolved into a powerful and versatile strategy for the construction of chiral molecules. Starting from readily available building blocks, the enantioselective asymmetric hydrogenation of unsaturated bonds offers a straightforward strategy for the rapid construction of isolated or contiguous stereogenic centers at both early and late stages. In this review, we present a comprehensive overview of asymmetric hydrogenation of diverse unsaturated bonds, categorized by structural types. In particular, we highlight the application of asymmetric hydrogenation strategies in the total synthesis of natural products and drugs.

PMID 42902835
Read full article →
PubMedNatural product reports2026-10-22

Natural products shape microbial ecology and disease in the cystic fibrosis airway.

Bhowmik Niladri N, Stubbendieck Reed M RM

Covering up to 2026Cystic fibrosis (CF) is a life-shortening autosomal recessive genetic disorder caused by mutation in the gene encoding the CF transmembrane conductance regulator (CFTR). Dysfunction in CFTR leads to the accumulation of thick and dehydrated mucus in the respiratory tract, which serves as a substrate for a complex microbiota that includes commensal oral and respiratory bacteria and opportunistic pathogenic bacteria and fungi. During chronic infections, these microbes persist in the airways and contribute to progressive lung tissue damage, ultimately leading to respiratory failure and premature death. Within this environment, microbes synthesize a diverse repertoire of natural products, including antimicrobials, siderophores and other metallophores, signaling molecules, toxins, and other virulence factors. In this review, we thoroughly discuss natural products produced by members of the CF airway microbiota, primarily the bacterial pathogens Burkholderia spp., Pseudomonas aeruginosa, and Staphylococcus aureus and the fungal pathogens Aspergillus fumigatus and Scedosporium spp. When known, we describe the biosynthesis and roles of these natural products in microbial persistence, interspecies interactions, and virulence in the CF airway. When these roles are unknown, we infer potential roles based on evidence from the literature in different disease contexts. Finally, we briefly highlight natural products produced by the CF microbiota as novel sources for developing new antimicrobials and as drug targets to treat disease.

PMID 42902746
Read full article →
PubMedJournal of the Korean Society of Radiology2026-10-22

Imaging and Histopathologic Features of Incidentally Detected Hepatic Perivascular Epithelioid Cell Tumors: A Case Report.

Jeong Pilwon P, Kim Jae Woon JW, Choi Joon Hyuk JH

Hepatic perivascular epithelioid cell tumor (PEComa) are rare mesenchymal neoplasms. The limited number of reported cases, along with nonspecific clinical symptoms and laboratory findings, often complicates accurate preoperative diagnosis. Here, we present a case of hepatic PEComa incidentally detected in a 64-year-old woman without underlying liver disease. We describe the clinical presentation, laboratory findings, CT and MRI features, and histopathological characteristics confirmed after surgical resection that may facilitate the diagnosis of hepatic PEComa.

PMID 42903030
Read full article →
PubMedZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2026-10-22

[Preliminary evaluation of the efficacy and safety of telitacicept in children with IgA nephropathy].

Chen Jie J, Yu Xiao-Xia XX, Shi Xiao-Song XS, Chen Bing B et al.

To preliminarily assess the efficacy and safety of telitacicept in pediatric IgA nephropathy (IgAN). Clinical data of 11 children with IgAN who received telitacicept in the Department of Pediatrics, Provincial Hospital Affiliated to Fuzhou University, from January 2024 to October 2025 were retrospectively collected. Parameters compared before and after treatment included 24-hour urinary protein, serum albumin, immunoglobulins (IgG, IgA, IgM), peripheral blood CD19+ cells, estimated glomerular filtration rate (eGFR), and glucocorticoid dosage. Adverse events were recorded. At 4, 12, 24, 36, and 48 weeks after treatment, 24-hour urinary protein was significantly lower than baseline (all P<0.05), with the greatest reduction at 12 weeks (P<0.001). Serum albumin increased compared with baseline, reaching statistical significance at 12, 24, and 36 weeks (all P<0.05). IgG and IgA levels decreased significantly at all time points (all P<0.05), and IgM showed an overall downward trend (P<0.05). CD19+ cell counts showed no significant change (P>0.05). Glucocorticoid dosage was significantly reduced (P<0.05), while eGFR showed no significant change (P>0.05). A total of 6 adverse event episodes were recorded, predominantly mild respiratory infections; no serious adverse events occurred. Telitacicept can effectively reduce proteinuria in children with IgAN and demonstrates an overall favorable safety profile.

PMID 42902722
Read full article →
PubMedChemical communications (Cambridge, England)2026-10-22

Picolinamide-directed palladium(II)-catalyzed regioselective hydroacyloxylation of unactivated alkenes.

Bakthadoss Manickam M, Yaswanth Alapati A, Shaw Raj Laxmi RL, Kavikumar Sivasubramaniyan S

A method for the palladium(II)-catalyzed highly regioselective hydroacyloxylation of unactivated alkenes with carboxylic acids is described using a picolinamide directing group via a Wacker-type nucleopalladation pathway. This novel strategy paves the way for generating very useful β-amino alcohols and esters from simple starting materials, which are important building blocks in many natural products and biologically active compounds. The transformation affords the desired products in good yields and exhibits broad compatibility with aromatic, aliphatic, and fatty carboxylic acids. In addition to forming valuable C-O bonds, the reaction generates a new stereogenic center, providing a synthetically valuable platform for further functionalization and diversification.

PMID 42902745
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about anti-varicella zoster immunoglobulins